X2Z Stock Overview
onesano S.A. engages in the research and development in the areas of dietetics, animal nutrition, bioremediation, and agrotechnological processes in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
onesano S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.26 |
| 52 Week High | zł0.33 |
| 52 Week Low | zł0.22 |
| Beta | 0.75 |
| 1 Month Change | -7.77% |
| 3 Month Change | 2.76% |
| 1 Year Change | -20.18% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| X2Z | DE Food | DE Market | |
|---|---|---|---|
| 7D | 3.2% | 0.7% | 2.5% |
| 1Y | -20.2% | -19.7% | 6.0% |
Return vs Industry: X2Z matched the German Food industry which returned -20.8% over the past year.
Return vs Market: X2Z underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| X2Z volatility | |
|---|---|
| X2Z Average Weekly Movement | 7.7% |
| Food Industry Average Movement | 4.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: X2Z has not had significant price volatility in the past 3 months.
Volatility Over Time: X2Z's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 51 | Jacek Kostrzewa | onesano.pl |
onesano S.A. engages in the research and development in the areas of dietetics, animal nutrition, bioremediation, and agrotechnological processes in Poland. The company provides human dietary supplement products under the Estrovita brand. It also offers Yarrowia Equinox; Yarrowia Canifelox; and Yarrowia Farminox; and dietary supplements, food additives, functional foods, and cosmetic raw materials.
onesano S.A. Fundamentals Summary
| X2Z fundamental statistics | |
|---|---|
| Market cap | €19.66m |
| Earnings (TTM) | -€1.48m |
| Revenue (TTM) | €2.84m |
6.9x
P/S Ratio-13.3x
P/E RatioIs X2Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X2Z income statement (TTM) | |
|---|---|
| Revenue | zł12.21m |
| Cost of Revenue | zł7.23m |
| Gross Profit | zł4.99m |
| Other Expenses | zł11.35m |
| Earnings | -zł6.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 22, 2024
| Earnings per share (EPS) | -0.097 |
| Gross Margin | 40.83% |
| Net Profit Margin | -52.10% |
| Debt/Equity Ratio | 0.05% |
How did X2Z perform over the long term?
See historical performance and comparison